What is Genygi?
Genygi is a fixed-dose combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. It contains two powerful active ingredients: Sofosbuvir (400mg) and Velpatasvir (100mg). This combination is known as a "pan-genotypic" treatment, meaning it is effective against all six major genotypes of the Hepatitis C virus (Genotypes 1–6).
How Genygi Works
The two components of Genygi work together to stop the virus from multiplying:
- Sofosbuvir: An RNA polymerase inhibitor that blocks the enzyme the virus needs to copy its genetic material.
- Velpatasvir: A protein inhibitor that prevents the virus from assembling and being released from infected cells.
By stopping viral replication, Genygi helps your immune system clear the infection and allows your liver to recover.
Indications and Usage
Genygi is indicated for adults with chronic HCV infection, with or without cirrhosis. In most cases, it is prescribed as a once-daily tablet for a duration of 12 weeks.
Side Effects
Most patients tolerate Genygi well. Common side effects may include headache, tiredness, or nausea. Always consult your doctor if you experience persistent symptoms or have concerns about your treatment.
Important Safety Information
Before starting Genygi, inform your healthcare provider about any other medications you are taking, especially those for heart conditions or other viral infections, as drug interactions can occur.
If you have questions about this medication or its availability, you can contact a GoMed pharmacist for professional guidance.